Signal detected: sterile fill-finish capacity
Matched to account fit, timing, and buyer context.
DHAX helps CDMOs, CROs, API suppliers, combination product manufacturers, and sterile fill-finish providers identify pharma and biotech companies showing signs of future outsourcing need.
Matched to account fit, timing, and buyer context.
Referrals, conferences, and preferred-vendor RFPs still matter. But in pharma services, the strongest conversations often begin earlier, when funding, CMC activity, supplier pressure, or program movement points to a possible need. The advantage is knowing which accounts to approach, why now, and who should hear from you first.
Each engagement is scoped around your services, target customer, exclusions, and commercial priorities. We look for market movement across regulatory, capital, personnel, clinical, and program categories that tend to surface pharma services demand.
Changes in development, clinical, CMC, or commercialization activity that may create a need for outside support.
Funding, partnerships, acquisitions, or expansion plans that may change budget, urgency, or supplier needs.
Signals that may point to manufacturing review, sourcing needs, continuity risk, or a search for stronger vendor options.
New commercial, CMC, quality, supply, or development leaders who may reopen partner and vendor conversations.
A single signal rarely tells the full story. We connect program activity, funding, CMC movement, supply pressure, leadership changes, and service fit into a clearer view of which accounts are worth pursuing, why the timing matters, and how to approach the conversation.
Relevant market movement across the pharma services landscape, from program and CMC activity to funding, leadership change, and supply pressure.
Signals are layered with your capabilities, target buyers, timing, and exclusions so the list points to companies that actually make sense for your team.
The signal work becomes commercial intelligence your team can use, with the account context and why-now angle needed for better outreach and follow-up.
We turn pharma market intelligence into managed outreach your team can see and act on. Your team stays involved where it matters: ICP direction, message approval, and follow-through on qualified interest.
We define the pharma services market you want to reach, the accounts that make sense for your capabilities, and the accounts that should stay out of the campaign.
Start with a focused first campaign, continue with a managed outreach cycle, and add commercial follow-through when qualified interest needs support. Each service has a clear role, so you can start where the opportunity is most defined.
A focused engagement to understand one market, prioritize the right accounts, run outreach, and see which conversations are worth pursuing.
Testing one market
Market focus, managed campaign, after-action recommendation
30 days, fixed scope
A managed cycle that keeps account monitoring, outreach, reply review, and reporting running once the market is defined.
Running ongoing outreach
Account monitoring, managed outreach, monthly review
90-day operating cycle
A scoped support layer that helps move qualified interest into active opportunity through prospect prep, follow-up, and next-step coordination.
Supporting active opportunities
Prospect prep, follow-up support, opportunity updates
Scoped support add-on
A Commercial Opportunity Sprint gives you a defined way to focus one pharma services market, prioritize the right accounts, shape the outreach, launch the campaign, and see which conversations are ready to move. Most start here because it creates a clear first step without committing to a larger BD system too early.
The advantage is not more outreach. It is knowing which pharma and biotech accounts are worth pursuing now, why the timing matters, and how to start a relevant conversation.